Matching articles for "glaucoma"
Issue 1759 · July 20, 2026
Omidenepag Isopropyl (Omlonti) for Glaucoma

The FDA has approved Omlonti (Ocuvex), a 0.002% ophthalmic solution of the prostaglandin EP 2 receptor agonist omidenepag isopropyl, for reduction of intraocular pressure (IOP) in patients with open-angle…

Med Lett Drugs Ther. 2026 Jul 20; 68(1759):114-6 doi:10.58347/tml.2026.1759b
The FDA has approved Omlonti (Ocuvex), a 0.002% ophthalmic solution of the prostaglandin EP 2 receptor agonist omidenepag isopropyl, for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Omidenepag is the first selective prostaglandin EP 2 receptor agonist to be approved in the US. It has been available in Japan since 2018.
Issue 1732 · July 7, 2025 Free
Addendum: Drugs for Open-Angle Glaucoma

Our recent article on glaucoma stated that systemic adverse effects of ophthalmic beta blockers include bradycardia. A reader suggested we should have also mentioned that they rarely cause heart block,…

Med Lett Drugs Ther. 2025 Jul 7; 67(1732):112 doi:10.58347/tml.2025.1732e
Our recent article on glaucoma stated that systemic adverse effects of ophthalmic beta blockers include bradycardia. A reader suggested we should have also mentioned that they rarely cause heart block, particularly in patients receiving other negative chronotropic drugs such as verapamil or diltiazem, and when that occurs, stopping the ophthalmic beta blocker may avoid insertion of a pacemaker.
Issue 1727 · April 28, 2025
Drugs for Open-Angle Glaucoma

Glaucoma is a progressive optic neuropathy associated with increased intraocular pressure (IOP; normal range 8-22 mm Hg), which is the only disease-related factor that can be modified. Topical drugs that lower…

Med Lett Drugs Ther. 2025 Apr 28; 67(1727):65-8 doi:10.58347/tml.2025.1727a
Glaucoma is a progressive optic neuropathy associated with increased intraocular pressure (IOP; normal range 8-22 mm Hg), which is the only disease-related factor that can be modified. Topical drugs that lower IOP are the first line of treatment for open-angle glaucoma.
Issue 1701 · April 29, 2024
iDose TR — A Travoprost Implant for Glaucoma

The FDA has approved iDose TR (Glaukos), an intracameral implant containing the prostaglandin analog (PGA) travoprost, for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular…

Med Lett Drugs Ther. 2024 Apr 29; 66(1701):70-1 doi:10.58347/tml.2024.1701d
The FDA has approved iDose TR (Glaukos), an intracameral implant containing the prostaglandin analog (PGA) travoprost, for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Travoprost is also available as a topical ophthalmic solution ( Travatan Z , and generics) for the same indication. iDose TR is the second ocular implant to become available in the US for this indication; Durysta , an intracameral implant containing the prostaglandin analog bimatoprost, was the first.
Issue 1603 · July 27, 2020
Durysta - A Bimatoprost Implant for Glaucoma

The FDA has approved an intracameral implant containing the prostaglandin analog bimatoprost ( Durysta – Allergan) for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular…

Med Lett Drugs Ther. 2020 Jul 27; 62(1603):116-7
The FDA has approved an intracameral implant containing the prostaglandin analog bimatoprost ( Durysta – Allergan) for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Bimatoprost is also available in 0.01% (Lumigan) and 0.03% (generics) ophthalmic solutions for the same indication and in a 0.03% solution (Latisse , and generics) for eyelash enhancement. Durysta is the first ocular implant to become available in the US for treatment of glaucoma.
Issue 1586 · December 2, 2019
Drugs for Common Eye Disorders

This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.

Med Lett Drugs Ther. 2019 Dec 2; 61(1586):187-94
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.
Issue 1585 · November 18, 2019
Cannabis and Cannabinoids

Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of…

Med Lett Drugs Ther. 2019 Nov 18; 61(1585):179-82
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.
Issue 1551 · July 16, 2018
Two New Drugs for Glaucoma

The FDA has approved two new ophthalmic drugs for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: latanoprostene bunod ( Vyzulta – Bausch and Lomb), a…

Med Lett Drugs Ther. 2018 Jul 16; 60(1551):117-20
The FDA has approved two new ophthalmic drugs for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: latanoprostene bunod ( Vyzulta – Bausch and Lomb), a modified prostaglandin analog, and netarsudil ( VRhopressa – Aerie), the first Rho kinase inhibitor to be approved in the US.
Issue 1421 · July 22, 2013
Brinzolamide/Brimonidine (Simbrinza) for Glaucoma

The FDA has approved Simbrinza (Alcon), an ophthalmic combination of the carbonic anhydrase inhibitor brinzolamide and the selective alpha 2 -adrenergic receptor agonist brimonidine, for reduction of…

Med Lett Drugs Ther. 2013 Jul 22; 55(1421):57-8
The FDA has approved Simbrinza (Alcon), an ophthalmic combination of the carbonic anhydrase inhibitor brinzolamide and the selective alpha 2 -adrenergic receptor agonist brimonidine, for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Simbrinza is the first product to combine drugs from these 2 classes.
Issue 1412 · March 18, 2013
Mitomycin Solution (Mitosol) for Glaucoma Surgery

A topical formulation of the antimetabolite mitomycin ( Mitosol – Mobius Therapeutics) has been approved by the FDA for adjunctive use in glaucoma surgery to reduce scarring. Compounding pharmacies have…

Med Lett Drugs Ther. 2013 Mar 18; 55(1412):24
A topical formulation of the antimetabolite mitomycin ( Mitosol – Mobius Therapeutics) has been approved by the FDA for adjunctive use in glaucoma surgery to reduce scarring. Compounding pharmacies have supplied the drug off-label for this purpose for many years.
Issue 123 · November 1, 2012
Drugs for Some Common Eye Disorders

Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of…

Treat Guidel Med Lett. 2012 Nov; 10(123):79-86
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of Treatment Guidelines on Drugs for Allergic Disorders.
Issue 1388 · April 16, 2012
Tafluprost (Zioptan) - A New Topical Prostaglandin for Glaucoma

The FDA has approved tafluprost ophthalmic solution ( Zioptan – Merck), a prostaglandin analog, for reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is being…

Med Lett Drugs Ther. 2012 Apr 16; 54(1388):31-2
The FDA has approved tafluprost ophthalmic solution ( Zioptan – Merck), a prostaglandin analog, for reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is being marketed as the first preservative-free topical prostaglandin
Issue 89 · January 1, 2010
Drugs for Some Common Eye Disorders

Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly…

Treat Guidel Med Lett. 2010 Jan; 8(89):1-8
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of Treatment Guidelines on Drugs for Allergic Disorders.
Issue 53 · January 1, 2007
Drugs for Some Common Eye Disorders

Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some…

Treat Guidel Med Lett. 2007 Jan; 5(53):1-8
Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves.
Issue 1106 · June 11, 2001 Free
Clarification: Drug Risk in Patients with Glaucoma

The Medical Letter article on Detrol LA and Ditropan XL (vol.43, page 28, April 2, 2001) stated that these drugs should not be used in patients with glaucoma. That statement is misleading because…

Med Lett Drugs Ther. 2001 Jun 11; 43(1106):52
The Medical Letter article on Detrol LA and Ditropan XL (vol.43, page 28, April 2, 2001) stated that these drugs should not be used in patients with glaucoma. That statement is misleading because anticholinergic or antimuscarinic drugs present a risk only to patients with untreated angle-closure (also called narrow-angle) glaucoma, which accounts for 10% of glaucomas in the USA. These drugs have no effect on the more common open-angle glaucoma, or on angle-closure glaucoma that has been treated by laser iridectomy.
Issue 1002 · June 6, 1997
Brimonidine - An Alpha2-Agonist for Glaucoma

Brimonidine tartrate 0.2% ophthalmic solution ( Alphagan - Allergan), a selective alpha2-adrenergic agonist, has been approved by the US Food and Drug Administration (FDA) for treatment of increased…

Med Lett Drugs Ther. 1997 Jun 6; 39(1002):54-5
Brimonidine tartrate 0.2% ophthalmic solution ( Alphagan - Allergan), a selective alpha2-adrenergic agonist, has been approved by the US Food and Drug Administration (FDA) for treatment of increased intraocular pressure due to open-angle glaucoma or ocular hypertension and for its prevention in patients undergoing argon laser trabeculoplasty.
Issue 987 · November 8, 1996
A Topical Prostaglandin for Glaucoma

Lantaoprost, a prostaglandin F2-alpha analog, has been approved by the FDA for topical treatment of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension refractory to…

Med Lett Drugs Ther. 1996 Nov 8; 38(987):100-1
Lantaoprost, a prostaglandin F2-alpha analog, has been approved by the FDA for topical treatment of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension refractory to other drugs.
Issue 956 · September 1, 1995
A Topical Carbonic Anhydrase Inhibitor For Glaucoma

Dorzolamide hydrochloride ( Trusopt - Merck), a thienothio-pyran-2-sulfonamide carbonic anhydrase inhibitor, was recently approved by the US Food and Drug Administration in a 2% ophthalmic solution for…

Med Lett Drugs Ther. 1995 Sep 1; 37(956):76-7
Dorzolamide hydrochloride ( Trusopt - Merck), a thienothio-pyran-2-sulfonamide carbonic anhydrase inhibitor, was recently approved by the US Food and Drug Administration in a 2% ophthalmic solution for treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Issue 828 · October 5, 1990
Metipranolol: A New Beta-blocker For Glaucoma

Metipranolol hydrocholride 0.3% ( OptiPranolol - Bausch & Lomb), a nonselective beta-adrenergic receptor blocking drug, was recently marketed of ophthalmic use to decrease intraolular pressure in ocular…

Med Lett Drugs Ther. 1990 Oct 5; 32(828):91-2
Metipranolol hydrocholride 0.3% ( OptiPranolol - Bausch & Lomb), a nonselective beta-adrenergic receptor blocking drug, was recently marketed of ophthalmic use to decrease intraolular pressure in ocular hypertension or chronic open-angle glaucoma. Beta-blockers available in the USA for treatment of glaucoma are listed in this article.